Stay updated with breaking news from Peter Hecht. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
A Phase 2b-ready Cyclerion Therapeutics drug candidate for a rare mitochondrial disease gets new life under a new startup led by a familiar face. Starup Tisento Therapeutics acquired the Cyclerion drug and is backed by a Series A round financing.
FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!
Following the transaction, the new company will be responsible for developing and commercializing zagociguat and CY3018.
Investors should not count on a return to the negative SBC relationship of the past 25 years.